Premium
Pancreas cancer: Therapeutic trials in metastatic disease
Author(s) -
Smithy James W.,
O'Reilly Eileen M.
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26359
Subject(s) - medicine , olaparib , pembrolizumab , pancreatic cancer , cancer , oncology , tumor microenvironment , immunotherapy , disease , cancer research , targeted therapy , stroma , immunohistochemistry , biochemistry , chemistry , polymerase , poly adp ribose polymerase , gene
Metastatic pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer‐related mortality in 2021. Cytotoxic therapies are the therapeutic mainstay for PDAC. The recent approval of olaparib as maintenance therapy for germline BRCA1/2 ‐mutated PDAC and pembrolizumab for mismatch repair deficient PDAC represent molecularly targeted approaches for this disease. Investigational therapeutic strategies include targeting the stroma, metabolism, tumor microenvironment, and the immune system, and selected approaches are reviewed herein.